← All trials
NCT07274696
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2025
- Primary completion
- Dec 1, 2027
- Completion date
- Dec 1, 2028
- First posted
- Dec 10, 2025
- Last posted
- Dec 10, 2025
- Enrollment
- 528
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sichuan UniversityLead sponsor
- Sanya People's HospitalCollaborator
- Sichuan UniversityCollaborator
- Sichuan UniversityCollaborator
- Sichuan UniversitySponsor investigator
- Sichuan UniversityCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.